GlassScriptPhysician profile
James S Molinari
NPI 1033793013
$2,533.06
in general payments reported to CMS, 2019-2025
23 companies · $39.18 in 2025
The $39.18 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $673 · 2023: $1,290 · 2024: $531 · 2025: $39.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,860.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $475.79 | 2022-2024 | |
| Lilly USA, LLC | $382.35 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $209.11 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.04 | 2022-2024 | Jardiance |
| Novo Nordisk INC | $190.43 | 2022-2024 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $161.54 | 2023-2024 | Spravato, Xarelto |
| Astrazeneca Pharmaceuticals LP | $149.29 | 2022-2023 | Breztri, Farxiga |
| Astellas Pharma US INC | $139.53 | 2022-2024 | Veozah |
| Merck Sharp & Dohme LLC | $108.84 | 2022-2023 | Gardasil 9, M-M-R II, Vaxneuvance |
| Pfizer INC. | $96.44 | 2023-2024 | |
| Glaxosmithkline, LLC. | $49.87 | 2023 | Bexsero, Shingrix, Arexvy |
| Exact Sciences Corporation | $47.63 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $46.72 | 2024 | Krystexxa, Otezla, Repatha |
| Hologic Sales and Service, LLC | $43.08 | 2024-2025 | Aptima |
| Sanofi Pasteur INC. | $42.06 | 2023-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $33.85 | 2024 | Voquezna |
| Cranial Technologies, INC | $28.80 | 2023-2024 | Doc Band |
| Idorsia Pharmaceuticals US INC | $26.14 | 2022-2023 | Quviviq |
| Medtronic, INC. | $25.38 | 2023 | Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.66 | 2023 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $17.39 | 2023 | Linzess |
| Seqirus USA INC | $14.85 | 2022 | |
| Jazz Pharmaceuticals INC. | $13.27 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Molinari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.